Business Context and Reporting Period
This Form 8-K Current Report was filed by Bone Biologics Corporation, a Delaware corporation, on March 3, 2016, covering the earliest event date of March 1, 2016. The filing addresses a change in the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance updates and does not contain financial performance data.
Material Changes
Effective March 1, 2016, Steve Warnecke resigned as a director of Bone Biologics Corporation. The Company stated that, to its knowledge, the resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the director resignation.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Mr. Warnecke's resignation.
- Confirm whether a replacement director has been appointed or if the seat remains vacant.
- Review subsequent filings for any undisclosed reasons regarding the resignation.